Survival analysis in overall older advanced NSCLC patients
The median follow-up time from EGFR-TKI treatment initiation was 19.4 months. The median PFS of all older advanced NSCLC patients treated with immune checkpoint inhibitors (ICIs) was 12.6 months (95% CI = 10.7–14.7), and the median OS time was 24.5 months (95% CI = 20.3–27.7).
Survival analysis in PP(+) and PP(–) older advanced NSCLC